Dear colleagues, We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email. Register to receive it 👉 buff.ly/N5gYtAc Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible. We are OncoAlert🚨 For Colleagues, by Colleagues Best, The Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3

Dear colleagues, We are already curating THE COMPLETE #ESMO26 NEWSLETTER 📰 our picks of the top trials presented in Madrid, together in one email. Register to receive it 👉 buff.ly/N5gYtAc Every newsletter is curated by oncologists, for colleagues working in cancer care. It’s our way of making science quick and accessible. We are OncoAlert🚨 For Colleagues, by Colleagues Best, The Network @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3

The OncoAlert #OAOnTheGO straight from #ESMO26 Can we omit BOTH radiotherapy and endocrine therapy after breast-conserving surgery in older women with low-risk early breast cancer? 🤔 Our Faculty Dr. Elisabetta Bonzano🇮🇹 breaks down the TOP-1 trial for OncoAlert: 🔹 792 patients, age >70, HR+/HER2−, 75% grade 1 🔹 5-year local recurrence: nearly 15%, despite careful selection 🔹 Breast cancer–specific survival remains excellent, but recurrences still mean more surgery and treatment De-escalation means balancing local control, survival and quality of life. EUROPA (RT alone vs ET alone) will add to the picture. . #BreastCancer Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76

More than a faculty and more than a network! The best oncology family I could ask for 🧡 So proud to be part of @OncoAlert and being PULSE at #ESMO26! Learning from brilliant colleagues, sharing the science in real time, and growing together along the way. By colleagues, for colleagues 🌍 @cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOn @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists

🎥 #OAOnTheGO Series in| #ESMO26 Madrid Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update! In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology. 🔬 Key takeaways: 📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years. 📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%. 📊 No new safety signals, with patients now more than 3 years off ribociclib. These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer. While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer? 🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert. Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76

The #OncoAlertTopTweet 🚨 #ESMO26 DAY 2 Post by @ProfGLongMIA 🚨 INTerpath-001 at #ESMO26: adding #intismeran autogene, an individualized mRNA neoantigen therapy, to pembrolizumab cut the risk of recurrence or death by 42% in high-risk resected #Melanoma. A first phase 3 win for personalized cancer vaccines 👇 #OncoAlert @jasonlukemd, @cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein3

🎥 #OAOnTheGO Series in| #ESMO26 Madrid Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update! In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology. 🔬 Key takeaways: 📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years. 📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%. 📊 No new safety signals, with patients now more than 3 years off ribociclib. These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer. While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer? 🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert. Pinging OncoAlert Breast Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc @Lucarecco @Dr_Oncologista @guiandri76

A Great time at the #OncoAlert5k Running Club Run at #ESMO26 Huge shout out to our members that despite the cold weather and darkness, brought a positive healthy attitude and just plain BROUGHT IT!! Looking forward to our Next Run in OUR HOME CITY of San Antonio Tx for #SABCS26 @cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein3

#ESMO26 Great start of Day 2 @myESMO with the #OncoAlertRun #Madrid26 Great organization by @weoncologists @OncoAlert It was 8°C but we made it 🔥👏🏽 👇🏽👇🏽

An OncoAlert #Podium2Screen from the #ESMO26 Presidential Session Presented by our @OncoALert 🚨faculty @tompowles1 Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65 🔬 Phase 3 VOLGA trial (n=695) Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC). Just PUBLISHED in @NEJM nejm.org/doi/full/10.1056/NE… Interim analysis; median event-free survival (EFS) follow-up: 22.9 months. ➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83) ➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance ➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control ➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control ✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS. 🎙️ Presenter: Thomas Powles 👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3

🎬 New #OAOnTheGo 🎥 from #ESMO26 Our #OncoAlertAF colleagues & Melanoma specialist Dr. @MarioBalsaMD (Hospital Clínic Barcelona) on treating patients who don’t fit the trials: 🤰 Melanoma in pregnancy: very limited data, and none at all for anti-LAG3 Transplant recipients: checkpoint inhibitors can work, but rejection occurs in ~1 in 3 Immunotherapy is never just about the tumor 👇 #ESMO26 #Melanoma @DrBetofMDPhD @cdanicas, @matteolambe, @NiuSanford, @GlopesMd, @PGrivasMDPhD, @brian_rini, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein

A Great Mid Day of 📊 #ESMO26 Day 2 🇪🇸 The conversation keeps growing: 🔥 37.1M potential reach 💬 2.5K posts on X 👥 645 voices from 30 countries Thanks to everyone sharing the science from Madrid 🙏 Real-time metrics by ACUVOX 👇 acuvox.io @cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus, @WeOncologists, @niklas_kluemper, @Markuseckstein3, @PTarantinoMD, @VivekSubbiah, @adamfeuerstein,@AntonioMaestre, @DanaFarber, @MSKCancerCenter,

Dear #ESMO26 We Are ALL @OncoAlert 🚨 For Colleagues...By Colleagues @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @scocmem @niklas_kluemper @Markuseckstein3 @AndreaNecchi @weoncologists